| Continuous maintenance with low-dose lansoprazole versus Helicobacter pylori eradication in the prevention of duodenal ulcer recurrence. | |
| | |
MedLine Citation:
|
PMID: 9755995 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND/AIMS: Reduction of gastric acid secretion by maintenance treatment with antisecretory agents and eradication of H. pylori by antibiotics constitute the most effective therapeutic options in preventing duodenal ulcer relapse. The aim of this study was to compare the effect of a 12-month low-dose lansoprazole maintenance treatment with H. pylori eradication on the rate of ulcer relapse in H. pylori-positive duodenal ulcer patients. METHODOLOGY: After a healing phase with lansoprazole 30 mg/die or lansoprazole 30-60 mg/die plus antibiotics (amoxycillin, tinidazole and colloidal bismuth subcitrate), 84 patients with healed duodenal ulcer entered the follow-up phase. Thirty-eight patients with persistent H. pylori infection received lansoprazole 15 mg at bedtime, whereas 46 in whom H. pylori was eradicated during the acute phase received no active therapy during the 12-month follow-up. The two groups were well balanced concerning all demographic characteristics. Clinical controls were performed every 3 months or sooner in the event of symptomatic relapse. RESULTS: In terms of per protocol analysis, the overall rate of ulcer relapse at 6 months was 5.5% (2/36) in the maintenance group and 0 (0/42) in the antibiotic group. The corresponding figures at 12 months were 20.5% (7/34) and 5.7% (2/35), respectively (p:ns, 95% CI for the difference -0.30+0.02). On intent to treat analysis, the rate of ulcer relapse at 6 months was 5.2% (2/38) in the first group and 0% (0/46) in the second group: at 12 months the corresponding figures were 19.4% (7/36) and 4.3% (2/46), respectively (p=0.06; CI 95%: +0.016+0.28). No significant side effects were observed during long-term maintenance with lansoprazole. CONCLUSIONS: Continuous maintenance with low-dose lansoprazole may constitute a valuable alternative to H. pylori eradication for the prevention of relapse and complications in duodenal ulcer patients not suitable for, or who have failed, H. pylori eradication. |
| | |
Authors:
|
F Parente; S Bargiggia; S Bollani; E Colombo; G Bianchi Porro |
Related Documents
:
|
9521955 - Treatment of symptomatic chronic adenotonsillar hypertrophy with amoxicillin/clavulanat... 16611285 - Bovine lactoferrin for helicobacter pylori eradication: an open, randomized, multicentr... 12571185 - Effect of various doses of gestogens on micronuclei frequency in human peripheral blood... 22191465 - Operational cures after interferon-alpha in patients with chronic myeloid leukemia in c... 23406435 - Angiographic and clinical outcomes after implantation of drug eluting stents in bifurca... 23202875 - Treating burn-associated joint contracture: results of an inpatient rehabilitation stre... |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Hepato-gastroenterology Volume: 45 ISSN: 0172-6390 ISO Abbreviation: Hepatogastroenterology Publication Date: 1998 Jul-Aug |
Date Detail:
|
Created Date: 1998-12-09 Completed Date: 1998-12-09 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8007849 Medline TA: Hepatogastroenterology Country: GREECE |
Other Details:
|
Languages: eng Pagination: 990-3 Citation Subset: IM |
Affiliation:
|
Department of Gastroenterology, L.Sacco University Hospital, Milan, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles Adult Anti-Ulcer Agents / therapeutic use* Drug Administration Schedule Duodenal Ulcer / drug therapy, prevention & control* Female Follow-Up Studies Helicobacter Infections / drug therapy*, prevention & control Helicobacter pylori* Humans Male Middle Aged Omeprazole / analogs & derivatives*, therapeutic use Recurrence / prevention & control Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 103577-45-3/lansoprazole; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Gamma-glutamyl transferase, intestinal alkaline phosphatase and beta-hexosaminidase activity in duod...
Next Document: Prognostic relevance of histomorphological parameters and DNA content and their therapeutic conseque...